Drug Shortage Report for BIVALIRUDIN FOR INJECTION

Last updated on 2022-02-04 History
Report ID 149848
Drug Identification Number 02435268
Brand name BIVALIRUDIN FOR INJECTION
Common or Proper name Bivalirudin for Injection 250 mg/vial SD Vial 10 mL
Company Name FRESENIUS KABI CANADA LTD
Market Status MARKETED
Active Ingredient(s) BIVALIRUDIN
Strength(s) 250MG
Dosage form(s) POWDER FOR SOLUTION
Route of administration INTRAVENOUS INTRAVENOUS
Packaging size 10 mL
ATC code B01AE
ATC description ANTITHROMBOTIC AGENTS
Reason for shortage Demand increase for the drug.
Anticipated start date 2021-11-24
Actual start date 2021-11-24
Estimated end date 2022-01-20
Actual end date 2022-01-21
Shortage status Resolved
Updated date 2022-02-04
Company comments Sandoz is an alternate supplier of Bivalirudin for Injection and have been informed of our impending supply interruption.
Health Canada comments
Tier 3 Status No
Contact Address 165 GALAXY BLVD, SUITE 100
TORONTO, ONTARIO
CANADA M9W 0C8
Company contact information

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v9 2022-02-04 French Compare
v8 2022-02-04 English Compare
v7 2021-12-24 French Compare
v6 2021-12-24 English Compare
v5 2021-12-03 French Compare
v4 2021-12-03 English Compare
v3 2021-11-25 English Compare
v2 2021-11-24 French Compare
v1 2021-11-24 English Compare

Showing 1 to 9 of 9